Relaxin enhances the oncogenic potential of human thyroid carcinoma cells

American Journal of Pathology

Volumn 169, Issue 2, 2006, Pages 617-632

  Hombach Klonisch, Sabine ^a   Bialek, Joanna ^d   Trojanowicz, Bogusz ^d   Weber, Ekkehard ^d   Holzhausen, Hans Jürgen ^d   Silvertown, Josh D ^b   Summerlee, Alastair J ^c   Dralle, Henning ^d   Hoang Vu, Cuong ^d   Klonisch, Thomas ^a,e  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF GUELPH   (Canada)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; CATHEPSIN L; ELASTIN; MITOGENIC AGENT; RECEPTOR PROTEIN; RELAXIN; RELAXIN RECEPTOR; RELAXIN RECEPTOR LGR7; RLN2 RELAXIN; UNCLASSIFIED DRUG;

ARTICLE; AUTOCRINE EFFECT; CARCINOGENESIS; CARCINOMA CELL; CELL INVASION; CELL MOTILITY; CELL STRAIN FTC 133; CELL STRAIN FTC 238; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; THYROID CARCINOMA;

EID: 33746588199     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.050876     Document Type: Article

References (59)

1. Ivell R, Einspanier A: Relaxin peptides are new global players. Trends Endocrinol Metab 2002, 13:343-348
2. Silvertown JD, Summerlee AJ, Klonisch T: Relaxin-like peptides in cancer. Int J Cancer 2003, 107:513-519
3. Plunkett ER, Squires BP, Richardson SJ: The effect of relaxin on thyroid weights in laboratory animals. J Endocrinol 1960, 21:241-246
4. Plunkett ER, Squires BP, Heagy FC: Effect of relaxin on thyroid function in the rat. J Endocrinol 1963, 26:331-338
5. Braverman LE, Ingbar SH: Effects of preparations containing relaxin on thyroid function in the female rat. Endocrinology 1963, 72:337-341
6. Adham IM, Burkhardt E, Benahmed M, Engel W: Cloning of a cDNA for a novel insulin-like peptide of the testicular Leydig cells. J Biol Chem 1993, 268:26668-26672
7. Pusch W, Balvers M, Ivell R: Molecular cloning and expression of the relaxin-like factor in the mouse testis. Endocrinology 1996, 137:3009-3013
8. Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD, Hsueh AJW: Activation of orphan receptors by the hormone relaxin. Science 2002, 295:671-674
9. Bartsch O, Bartlick B, Ivell R: Phosphodiesterase 4 inhibition synergized with relaxin signaling to promote decidualization of human endometrial stromal cells. J Clin Endocrinol Metab 2004, 89:324-334
10. Bartsch O, Bartlick B, Ivell R: Relaxin signalling links tyrosine phosphorylation to phosphodiesterase and adenylyl cyclase activity. Mol Hum Reprod 2001, 7:799-809
11. Parsell DA, Mak JY, Amento EP, Unemori EN: Relaxin binds to and elicits a response from cells of the human monocytic cell line, THP-1. J Biol Chem 1996, 271:27936-27941
12. Bogatcheva NV, Truong A, Feng S, Engel W, Adham IM, Agoulnik AI: GREAT/LGR8 is the only receptor for insulin-like 3 peptide. Mol Endocrinol 2003, 17:2639-2646
13. Hombach-Klonisch S, Hoang-Vu C, Kehlen A, Hinze R, Holzhausen HJ, Weber E, Fischer B, Dralle H, Klonisch T: INSL-3 is expressed in human hyperplastic and neoplastic thyrocytes. Int J Oncol 2003, 22:993-1001
14. Tashima LS, Mazoujian G, Bryant-Greenwood GD: Human relaxins in normal, benign and neoplastic breast tissue. J Mol Endocrinol 1994, 12:351-364
15. Silvertown JD, Geddes BJ, Summerlee AJS: Adenovirus-mediated expression of human prorelaxin promotes the invasive potential of canine mammary cancer cells. Endocrinology 2003, 144:3683-3691
16. Radestock Y, Hoang-Vu C, Hombach-Klonisch S: Relaxin downregulates the calcium binding protein S100A4 in MDA-MB-231 human breast cancer cells. Ann NY Acad Sci 2005, 1041:462-469
17. Klonisch T, Mustafa T, Bialek J, Radestock Y, Holzhausen H-J, Dralle H, Hoang-Vu C, Hombach-Klonisch S: Human medullary thyroid carcinoma (MTC): a source and potential target for relaxin-like hormones. Ann NY Acad Sci 2005, 1041:449-461
18. Bigazzi M, Brandi ML, Bani G, Sacchi TB: Relaxin influences the growth of MCF-7 breast cancer cells. Mitogenic and antimitogenic action depends on peptide concentration. Cancer 1992, 70:639-643
19. Binder C, Hagemann T, Hausen B, Schulz M, Einspanier A: Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteinases. Mol Hum Reprod 2002, 8:789-796
20. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning-A Laboratory Manual, vol. 3, ed 2. Edited by Maniatis T. Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 1989, appendix E5
21. Dschietzig T, Richter C, Bartsch C, Laule M, Armbruster FP, Baumann G, Stangl K: The pregnancy hormone relaxin is a player in human heart failure. FASEB J 2001, 15:2187-2195
22. Fiebiger E, Meraner P, Weber E, Fang IF, Stingl G, Ploegh H, Maurer D: Cytokines regulate proteolysis in major histocompatibility complex class II-dependent antigen presentation by dendritic cells. J Exp Med 2001, 193:881-892
23. Tolosa E, Li W, Yasuda Y, Wienhold W, Denzin LK, Lautwein A, Driessen C, Schnorrer P, Weber E, Stevanovic S, Kurek R, Melms A, Bromme D: Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J Clin Invest, 2003, 112:517-526
24. Yasuda Y, Li Z, Greenbaum D, Bogyo M, Weber E, Bromme D: Cathepsin V, a novel and potent elastolytic activity expressed in activated macrophages. J Biol Chem 2004, 279:36761-36770
25. Chapman HA, Riese RJ, Shi GP: Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 1997, 59:63-88
26. Kamat AA, Feng S, Bogatcheva NV, Truong A, Bishop CE, Agoulnik AI: Genetic targeting of relaxin and insulin-like factor 3 receptors in mice. Endocrinology 2004, 145:4712-4720
27. Zarreh-Hoshyari-Khah R, Bartsch O, Einspanier A, Pohnke Y, Ivell R: Bioactivity of recombinant prorelaxin from the marmoset monkey. Regul Pept 2001, 97:139-146
28. Marriott D, Gillece-Castro B, Gorman CM: Prohormone convertase-1 will process prorelaxin, a member of the insulin family of hormones. Mol Endocrinol 1992, 6:1441-1450
29. Vu AL, Green CB, Roby KF, Soares MJ, Fei DT, Chen AB, Kwok SC: Recombinant porcine prorelaxin produced in Chinese hamster ovary cells is biologically active. Life Sci 1993, 52:1055-1061
30. Masini E, Bani D, Bello MG, Bigazzi M, Mannaioni PF, Sacchi TB: Relaxin counteracts myocardial damage induced by ischemia-reperfusion in isolated guinea pig hearts: evidence for an involvement of nitric oxide. Endocrinology 1997, 138:4713-4720
31. Kamat AA, Feng S, Agoulnik IU, Kheradmand F, Bogatcheva NV, Coffey D, Sood AK, Agoulnik AI: The role of relaxin in endometrial cancer. Cancer Biol Ther 2005, 5:e1-e7
32. Binder C, Hagemann T, Husen B, Schulz M, Einspanier A: Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix-metalloproteinases. Mol Hum Reprod 2002, 8:789-796
33. Wyatt TA, Sisson JH, Forget MA, Bennett RG, Hamel FG, Spurzem JR: Relaxin stimulates bronchial epithelial cell PKA activation, migration, and ciliary beating. Exp Biol Med 2002, 227:1047-1053
34. Unemori EN, Lewis M, Constant J, Arnold G, Grove BH, Normand J, Deshpande U, Salles A, Pickford LB, Erikson ME, Hunt TK, Huang X: Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regen 2000, 8:361-370
35. Klonisch T, Müller-Huesmann H, Riedel M, Kehlen A, Bialek J, Radestock Y, Holzhausen H-J, Steger K, Ludwig M, Weidner W, Hoang-Vu C, Hombach-Klonisch S: INSL3 in the benign hyperplastic and neoplastic human prostate gland. Int J Oncol 2005, 27:307-315
36. Khasigov PZ, Podobed OV, Gracheva TS, Salbiev KD, Grachev SV, Berezov TT: Role of matrix metalloproteinases and their inhibitors in tumor invasion and metastasis. Biochemistry 2003, 68:711-717
37. Jiang Y, Goldberg ID, Shi YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002, 21:2245-2252
38. Kraiem Z, Korem S: Matrix metalloproteinases and the thyroid. Thyroid 2000, 10:1061-1069
39. Binder C, Simon A, Binder L, Hagemann T, Schulz M, Emons G, Trumper L, Einspanier A: Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients. Breast Cancer Res Treat 2004, 87:157-166
40. Lennon-Dumenil AM, Bakker AH, Wolf-Bryant P, Ploegh HL, Lagaudriere-Gesbert C: A closer look at proteolysis and MHC-class-II-restricted antigen presentation. Curr Opin Immunol 2002, 14:15-21
41. Lauritzen E, Moller S, Leerhoy J: Leucocyte migration inhibition in vitro with inhibitors of aspartic and sulphhydryl proteinases. Acta Pathol Microbiol Immunol Scand [C] 1984, 92:107-112
42. Cataldo AM, Nixon RA: Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc Natl Acad Sci USA 1990, 87:3861-3865
43. Adamec E, Mohan PS, Cataldo AM, Vonsattel JP, Nixon RA: Up-regulation of the lysosomal system in experimental models of neuronal injury: implications for Alzheimer's disease. Neuroscience 2000, 100:663-675
44. Leto G, Tumminello FM, Crescimanno M, Flandina C, Gebbia N: Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications. Clin Exp Metastasis 2004, 21:91-106
45. Leto G, Gebbia N, Rausa L, Tumminello FM: Cathepsin D in the malignant progression of neoplastic diseases (review). Anticancer Res 1992, 12:235-240
46. Metaye T, Kraimps JL, Goujon JM, Fernandez B, Quellard N, Ingrand P, Barbier J, Begon F: Expression, localisation, and thyrotropin regulation of cathepsin D in human thyroid tissues. J Clin Endocrinol Metab 1997, 82:3383-3388
47. Metaye T, Millet C, Kraimps JL, Aubouin B, Barbier J, Begon F: Estrogen receptors and cathepsin D in human thyroid tissue. Cancer 1993, 72:1991-1996
48. Kraimps JL, Metaye T, Millet C, Margerit D, Ingrand P, Goujon JM, Levillain P, Babin P, Begon F, Barbier J: Cathepsin D in normal and neoplastic thyroid tissues. Surgery 1995, 118:1036-1040
49. Krueger S, Kellner U, Buehling F, Roessner A: Cathepsin L antisense oligonucleotides in a human osteosarcoma cell line: effects on the invasive phenotype. Cancer Gene Ther 2001, 8:522-528
50. Kirschke H, Eerola R, Hopsu-Havu VK, Bromme D, Vuorio E: Antisense RNA inhibition of cathepsin L expression reduces tumorigenicity of malignant cells. Eur J Cancer 2000, 36:787-795
51. Dohchin A, Suzuki JI, Seki H, Masutani M, Shiroto H, Kawakami Y: Immunostained cathepsins B and L correlate with depth of invasion and different metastatic pathways in early stage gastric carcinoma. Cancer 2000, 89:482-487
52. Urbich C, Heeschen C, Aicher A, Sasaki K, Bruhl T, Farhadi MR, Vajkoczy P, Hofmann WK, Peters C, Pennacchio LA, Abolmaali ND, Chavakis E, Reinheckel T, Zeiher AM, Dimmeler S: Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med 2005, 11:206-213
53. De Stefanis D, Demoz M, Dragonetti A, Houri JJ, Ogier-Denis E, Codogno P, Baccino FM, Isidoro C: Differentiation-induced changes in the content, secretion, and subcellular distribution of lysosomal cathepsins in the human colon cancer HT-29 cell line. Cell Tissue Res 1997, 289:109-117
54. Von Figura K, Hasilik A: Lysosomal enzymes and their receptors. Annu Rev Biochem 1986, 55:167-193
55. Laurant-Matha V, Maruani-Herrmann S, Prebois C, Beaujouin M, Glondu M, Noel A, Alvarez-Gonzalez ML, Blacher S, Coopman P, Baghdiguian S, Gilles C, Loncarek J, Freiss G, Vignon F, Liaudet-Coopman E: Catalytically inactive human cathepsin D triggers fibroblast invasive growth. J Cell Biol 2005, 168:489-499
56. Koike M, Shibata M, Ohsawa Y, Nakanishi H, Koga T, Kametaka S, Waguri S, Momoi T, Kominami E, Peters C, Von Figura K, Saftig P, Uchiyama Y: Involvement of two different cell death pathways in retinal atrophy of cathepsin D-deficient mice. Mol Cell Neurosci 2003, 22:146-161
57. Nakanishi H, Zhang J, Koike M, Nsihioku T, Okamoto Y, Kominami E, Von Figura K, Peters C, Yamamoto K, Saftig P, Uchiyama Y: Involvement of nitric oxide released from microglia-macrophages in pathological changes of cathepsin D-deficient mice. J Neurosci 2001, 21:7526-7533
58. Saftig P, Hetman M, Schmahl W, Weber K, Heine L, Mossmann H, Koster A, Hess B, Evers M, Von Figura K, Peters C: Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J 1995, 14:3599-3608
59. Radestock Y, Hoang-Vu C, Hombach-Klonisch S: Relaxin downregulates the calcium binding protein S100A4 in MDA-MB-231 human breast cancer cells. Ann NY Acad Sci 2005, 1041:462-469